Welcome to your daily round-up of everything happening in the world of neurorehabilitation.
Research news
A structured workflow for biomarker-based diagnosis
Due the vital need for timely and accurate diagnosis across health systems, 11 European scientific societies have joined forces to define a structured workflow for biomarker-based diagnosis of neurocognitive disorders.
Heart attack significantly increases risk of other health conditions
A major new study from the University of Leeds has shown that having a heart attack significantly increases the risk of developing other serious long-term health conditions. In the largest study of its kind, researchers analysed more than 145 million records covering every adult patient admitted to hospital over a nine-year period to establish the risk of long-term health outcomes following a heart attack.
Physical activity post-concussion in children and adolescents
Findings from a new study of children and adolescents with acute concussion suggest that moderate-to-vigorous-intensity physical activity reduced symptoms up to a certain threshold but appeared to offer no further benefit in symptom reduction beyond that point.
Genetic therapy holds promise for ALS and dementia
Neuroscientists at Macquarie University in Australia have developed a single-dose genetic medicine that has been proven to halt the progression of both ALS and frontotemporal dementia in mice – and may even offer the potential to reverse some of the effects of the fatal diseases. It may also hold opportunities for treating more common forms of dementia, such as Alzheimer’s disease.
Laquinimod study for Huntington’s Disease
A new study has shown that treatment with laquinimod did not impact motor symptoms in patients with Huntington’s Disease, but did significantly reduce caudate volume loss compared with placebo at week 52.
Company news
Vamorolone safety for patients with Duchenne Muscular Dystrophy
Santhera has announced the publication of its paper, Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in patients with Duchenne Muscular Dystrophy in the journal Neurology. The findings demonstrated the efficacy and benefits in safety and tolerability of treatment with vamorolone over 48 weeks, and also demonstrated safety benefits in patients switching from standard of care corticosteroids in terms of recovery of bone health and growth.
MARINA-OLE™ Trial in people living with Myotonic Dystrophy Type 1
Avidity Biosciences will be presenting its new AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in people living with Myotonic Dystrophy Type 1 (DM1) at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference being held March 3-6, 2024, in Orlando, Florida.
Technology
Detecting stroke with portable MRI
A new, portable bedside MRI has shown promise for detecting a high percentage of stroke-related infarct on high-field MRI in those with acute ischemic stroke, with better performance on larger sized infarcts, according to a poster from the International Stroke Conference.
